Suppr超能文献

α-硫辛酸治疗糖尿病性单神经病变

Treatment for diabetic mononeuropathy with alpha-lipoic acid.

作者信息

Tankova T, Cherninkova S, Koev D

机构信息

Clinic of Diabetology,Clinical Centre of Endocrinology, Clinic of Neurology, Medical University, Sofia, Bulgaria.

出版信息

Int J Clin Pract. 2005 Jun;59(6):645-50. doi: 10.1111/j.1742-1241.2005.00452.x.

Abstract

Twenty-three diabetic patients -- 16 men and seven women (mean age: 50.7 +/- 17.4 years; mean duration of diabetes: 13.6 +/- 6.9 years) -- with diabetic mononeuropathy of the cranial nerves participated in the study. Four of them were with mononeuropathia multiplex and total ophthalmoplegia, affecting the oculomotor, trochlear and abducent nerves; 12 with paresis of the oculomotor nerve, one -- of the trochlear nerve and six -- of the abducent nerve. They were treated with alpha-lipoic acid (600 mg) for 10 days daily intravenously, thereafter one film tablet of 600 mg daily for 60 days. On the 10th day, we found significant improvement in the clinical signs of diabetic mononeuropathy - double vision, motility and position of the eyeball, ptosis of the upper eyelid and mydriasis. The mean period of oral treatment was 69.1 +/- 23.8 days, following the 10-day intravenous application of alpha-lipoic acid, and full recovery of the diabetic mononeuropathy was achieved with this therapeutic approach. Peripheral neuropathy was present in 17 patients (74%). On the 10th day, we established a decrease in total symptom score by an average of 2.7 +/- 1.4 points and by the end of the treatment period it was improved by 5.9 +/- 1.9 points (p = 0.04). On the 10th day, we found a decrease of 33% in foot pain and by the end of the second month, it fell by 65.5% (p < 0.0001). Vibration perception threshold was reduced in these patients at entry -- mean: 2.42 +/- 1.8 at the great toe, 2.89 +/- 1.8 at the first metatarsal and 3.65 +/- 1.7 at the medial malleolus. By the end of the second month, it reached mean 4.7 +/- 1.8 (p < 0.002) at the great toe, 4.92 +/- 2.1 (p = 0.004) at the first metatarsal and 5.3 +/- 1.4 (p < 0.01) at the medial malleolus. Cardiovascular autonomic neuropathy was present in two of the patients and there was improvement after treatment in the Ewing's tests -- Valsalva manoeuvre, deep-breathing test and lying-to-standing test. The results of our study demonstrate that alpha-lipoic acid appears to be an effective drug in the treatment for not only peripheral and autonomic diabetic neuropathy, but also diabetic mononeuropathy of the cranial nerves leading to full recovery of the patients.

摘要

23例糖尿病性单神经病患者(16例男性,7例女性,平均年龄:50.7±17.4岁;糖尿病平均病程:13.6±6.9年)参与了本研究,这些患者均患有颅神经糖尿病性单神经病。其中4例患有多灶性单神经病和完全性眼肌麻痹,累及动眼神经、滑车神经和展神经;12例动眼神经麻痹,1例滑车神经麻痹,6例展神经麻痹。他们接受了α-硫辛酸(600mg)治疗,静脉注射10天,每日1次,之后每日口服1片600mg,持续60天。在第10天时,我们发现糖尿病性单神经病的临床症状有显著改善,如复视、眼球运动和位置、上睑下垂及瞳孔散大。在静脉注射α-硫辛酸10天后,口服治疗的平均疗程为69.1±23.8天,采用这种治疗方法糖尿病性单神经病完全恢复。17例患者(74%)存在周围神经病变。在第10天时,我们发现总症状评分平均下降2.7±1.4分,到治疗期末改善了5.9±1.9分(p = 0.04)。在第10天时,我们发现足部疼痛减轻了33%,到第二个月末,疼痛减轻了65.5%(p < 0.0001)。这些患者在入组时振动觉阈值降低,大脚趾平均为2.42±1.8,第一跖骨处平均为2.89±1.8,内踝处平均为3.65±1.7。到第二个月末,大脚趾平均达到4.7±1.8(p < 0.002),第一跖骨处为4.92±2.1(p = 0.004),内踝处为5.3±1.4(p < 0.01)。2例患者存在心血管自主神经病变,在治疗后尤因试验(瓦尔萨尔瓦动作、深呼吸试验和卧立位试验)有所改善。我们的研究结果表明,α-硫辛酸似乎是一种有效的药物,不仅可用于治疗周围性和自主性糖尿病神经病变,还可用于治疗颅神经糖尿病性单神经病,使患者完全康复。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验